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ApoE and Clusterin Cooperatively Suppress A
Levels and Deposition: Evidence that ApoE
Regulates Extracellular A Metabolism In Vivo
and insoluble forms with a high  sheet content is a key
event in the pathogenesis of Alzheimer’s disease (AD)
(Sisodia, 1999). Autosomal dominant forms of early-
onset familial AD appear to result from over-production
of a more amyloidogenic form of A, A42, that over many
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Unlike the mutations in genes that lead to familial AD,
most evidence suggests that apoE has no effect on ASummary
synthesis (Biere et al., 1995). Studies also suggest that
another apolipoprotein, produced at similar levels in theApolipoprotein E (apoE) and clusterin can influence
brain as apoE, known as clusterin (also called apolipo-structure, toxicity, and accumulation of the amyloid-
protein J) (May and Finch, 1992), similarly acts as an A(A) peptide in brain. Both molecules may also be
chaperone, regulating the conversion of A to insolubleinvolved in A metabolism prior to its deposition. To
forms as well as its toxicity (Oda et al., 1995; Boggs etassess this possibility, we compared PDAPP trans-
al., 1996; Matsubara et al., 1996; Lambert et al., 1998;genic mice that develop age-dependent A accumula-
DeMattos et al., 2002c). While these studies demon-tion in the absence of apoE or clusterin as well as in
strate that apoE and clusterin are involved in regulating
the absence of both proteins. apoE/ and clusterin/
the process of A aggregation in vitro and in vivo,
mice accumulated similar A levels but much less
whether they play a role in the metabolism of soluble
fibrillar A. In contrast, apoE//clusterin/ mice had A independent of an effect on A synthesis has not
both earlier onset and markedly increased A and am- been determined. To further assess this issue, we uti-
yloid deposition. Both apoE/ and apoE//clusterin/ lized a transgenic mouse model in which the human
mice had elevated CSF and brain interstitial fluid A, amyloid precursor protein (APP) with a familial AD muta-
as well as significant differences in the elimination tion (V717F) is expressed in the brain (PDAPP mice).
half-life of interstitial fluid A measured by in vivo mi- These mice develop age-dependent A deposition that
crodialysis. These findings demonstrate additive ef- is morphologically similar to that seen in AD (Games et
fects of apoE and clusterin on influencing A deposi- al., 1995; Bales et al., 1997). We bred PDAPP mice to
tion and that apoE plays an important role in regulating apoE/ and clusterin/ mice and then compared the
extracellular CNS A metabolism independent of A ensuing pathology in the absence of apoE, in the ab-
synthesis. sence of clusterin, and in the absence of both molecules.
In contrast to our predictions, PDAPP, apoE//clus-
Introduction terin/ (double knockout) mice had an early onset and
marked increase in A deposition. There was also an
Data from genetic, biochemical, and animal model stud- increase in soluble A species in both the brain and
ies strongly support the hypothesis that the conversion CSF prior to A deposition with no evidence for altered
of the normally soluble amyloid- (A) peptide to soluble APP processing. Interestingly, assessment of a pool of
A in the brain interstitial fluid (ISF) that is measurable
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Figure 1. Early Onset and Increase of A Deposition in apoE/clusterin Double Knockout Mice
A immunostaining was performed in PDAPP mice of the genotypes listed. At 6 months of age, PDAPP mice that lacked expression of both
apoE and clusterin (apoE//clusterin/) had already developed hippocampal A deposition whereas all other genotypes had no A deposits
at this age. By 12 months of age, PDAPP mice of all genotypes had A deposition; however, apoE//clusterin/ mice had markedly increased
A load. Photomicrographs are representative of animals from each group (n  10–20 per group). Magnification, 20.
life of this pool. Together, these data demonstrate that, layer of the dentate gyrus. As previously shown (Bales
et al., 1999; Holtzman et al., 1999), PDAPP, apoE/ micein addition to a role for both apoE and clusterin in influ-
had more diffuse appearing A IR deposits with promi-encing the process of A aggregation, apoE plays an
nent deposition in the dentate hilus with little to no stain-important role in regulating the metabolic pathway that
ing in the molecular layer. PDAPP, clusterin/ mice hadcontrols the elimination of soluble A in the brain extra-
predominantly diffuse A IR deposits with a similar pat-cellular space.
tern as seen in PDAPP mice expressing clusterin (De-
Mattos et al., 2002c). Interestingly, apoE/clusterin dou-Results
ble knockout mice had A deposits that were not only
more numerous and filled all parts of the hippocampusapoE/clusterin Double Knockout Mice Have
and some of the cortex by 12 months of age, thereMarkedly Increased A Deposition
appeared to be an abundance of both compact and
To assess the effects of apoE and clusterin on Ametab-
diffuse plaques (Figure 1). Plaque distribution was simi-
olism and structure, we compared PDAPP mice to
lar to that seen in mice that expressed both apoE and
PDAPP, apoE/; PDAPP, clusterin/, and PDAPP, clusterin.
apoE//clusterin/ mice. At 3 months of age, there was As shown previously, although A IR deposits are
no A deposition or amyloid in any of the genotypes as present in PDAPP, apoE/ and PDAPP, clusterin/
assessed by both A immunostaining and by thiofla- mice, there were significantly less thioflavine-S-positive
vine-S staining. By 6 months of age, there was still little (or true amyloid) deposits in the absence of each mole-
to no A deposition in any of the groups with the excep- cule alone (Figures 2C and 2D). Since apoE and clusterin
tion of the apoE/clusterin double knockout mice (Figure independently contribute to A fibril formation in vivo
1). The majority of these mice (10 out of 12) had substan- (Bales et al., 1997, 1999; Holtzman et al., 2000b; De-
tial deposition by this age. By 12 months of age, mice Mattos et al., 2002c), one might expect that there would
of all genotypes had A deposits in both the hippocam- be even less fibril formation in the absence of both
pus and cortex, although PDAPP, apoE//clusterin/ molecules. In contrast, we found that PDAPP, apoE//
mice had significantly greater A and amyloid burden clusterin/ mice had significantly greater levels of thio-
(Figures 1 and 2). These striking results were not pre- flavine-S-positive deposits than the other genotypes
dicted, since APP transgenic mice lacking either apoE (Figure 2C). Further, the overall percent of A IR deposits
or clusterin were previously shown to have much less that were thioflavine-S-positive in the PDAPP, apoE//
amyloid burden than mice expressing these proteins clusterin/ mice was not significantly different that in
(Bales et al., 1997, 1999; Holtzman et al., 2000b; De- PDAPP mice in the presence of both proteins (Figure
Mattos et al., 2002c). 2D). This suggested the possibility that an effect of apoE
In addition to the quantitative differences in A immu- and clusterin on A metabolism distinct from their ef-
noreactivity (IR) between the genotypes, there were also fects on fibrillogenesis was being unmasked in the ab-
differences in the plaque location and morphology be- sence of both molecules. Since PDAPP mice that lack
tween the groups (Figure 1). PDAPP mice that expressed apoE or clusterin alone have previously been shown to
both apoE and clusterin had prominent deposits that have less amyloid as well as less neuritic dystrophy
were both diffuse and compact in appearance through- (Bales et al., 1997; Holtzman et al., 2000a; DeMattos et
al., 2002c), we assessed neuritic dystrophy at 6 and 12out the hippocampus including within the molecular
apoE and clusterin Suppress A Deposition
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Figure 2. A and Amyloid Load Are In-
creased in the Absence of apoE and clusterin
At 12 months of age, the percent area of the
hippocampus (A) and cortex (B) covered by
A immunoreactivity (IR) (percent A load) is
significantly greater in PDAPP mice that are
apoE//clusterin/ (n  12) as compared to
PDAPP mice that are apoE//clusterin/
(n  21), apoE//clusterin/ (n  23), or
apoE//clusterin/ (n  13). (C) PDAPP,
apoE//clusterin/ mice also had signifi-
cantly greater percent area of the hippocam-
pus covered by thioflavine-S staining (per-
cent thio-S load) than PDAPP mice of other
genotypes. (D) When comparing thioflavine-S
load as a percentage of A load, both PDAPP,
apoE//clusterin/ and PDAPP, apoE//
clusterin/ mice had greater levels than
PDAPP mice lacking only apoE or only clus-
terin.
months of age. There was a similar extent of neuritic vine-S-negative diffuse A deposits that are highly en-
riched in insoluble A42.dystrophy surrounding thioflavine-S-positive plaques in
The early and overall marked increase in A levelsthe apoE/clusterin double knockout mice as compared
and deposition at 6 and 12 months of age in apoE/to PDAPP mice expressing both molecules. This sug-
clusterin double knockout mice suggest the possibilitygests that apoE and clusterin can facilitate but are not
that one or both molecules may be playing a role in Arequired to form mature amyloid fibrils that are associ-
metabolism that is over-riding part of their effect onated with local toxicity in vivo.
promotion of A fibril formation. If apoE or clusterin is
having an effect on A metabolism, levels of soluble AapoE and clusterin Cooperatively Regulate
should be altered prior to the occurrence of A deposi-Soluble A Levels Prior to A Deposition
tion. To directly assess whether apoE and clusterin wereapoE and clusterin have both been shown to bind to both
directly involved in the clearance/metabolism of solublesoluble and fibrillar A (Ghiso et al., 1993; Strittmatter et
A, we measured the level of A40 and A42 in severalal., 1993a; LaDu et al., 1994, 1995; Wisniewski et al.,
body compartments prior to A deposition for all of the
1997; Russo et al., 1998). If either of these proteins plays
genotypes. At 3 months, PDAPP, apoE//clusterin/
a role in soluble A metabolism in addition to their role mice had significantly higher levels of carbonate soluble
in A aggregation, one would predict that in the absence and insoluble A40 and A42 in the hippocampus as com-of either one or both molecules there would be altered pared to mice of other genotypes (Figure 4). Because
levels of A both prior and subsequent to A deposition. the transgenic animals lack any deposited A at this
We assessed levels of A40 and A42 in both carbonate age, the carbonate insoluble A likely represents an
soluble and insoluble hippocampal homogenates at 3 intracellular pool. A in brain homogenates of PDAPP
months (prior to A deposition) and 12 months of age mice contains a mixture of both intra- and extracellular
(subsequent to A deposition). At 12 months of age, A produced by neurons (DeMattos et al., 2001; Cirrito
as predicted from the histological findings, PDAPP, et al., 2003). Most apoE and clusterin in the brain is
apoE//clusterin/ mice had the highest total tissue produced and secreted by glial cells. If the binding of
levels of A40 and A42 as compared to other genotypes apoE and clusterin to soluble A in the extracellular
(Figure 3). While levels of soluble A40 and A42 were space influences A clearance/metabolism, one predic-
highest in apoE//clusterin/ mice (Figures 3A and 3B), tion is that in their absence there would be increased
insoluble A40 was similar in PDAPP and PDAPP, A levels in fluids in direct communication with the extra-
apoE//clusterin/ mice (Figure 3C) and insoluble A42 cellular space of the brain (e.g., cerebrospinal fluid
was highest in PDAPP, apoE/ and PDAPP, apoE// [CSF]). Directly supporting this hypothesis, we found
clusterin/ mice (Figure 3D). The elevated levels of insol- that CSF A40 and A42 levels were elevated in the ab-
uble A40 in the PDAPP and PDAPP, apoE//clusterin/ sence of apoE alone as well as in the apoE/clusterin
mice is in concert with the higher levels of thioflavine- double knockout mice at 3 months of age (Figures 5A
S-positive amyloid found in these two genotypes. In and 5B). There was a greater increase of A40 in apoE//
vivo, a high percentage of thioflavine-S-positive A de- clusterin/ versus apoE/ mice, although a similar in-
posits, as is present in amyloid angiopathy, has been crease in A42 was present in both apoE/ and apoE//
shown to be associated with increased deposition of clusterin/ (Figure 5B). Although there was no signifi-
A40 (Joachim et al., 1988). In contrast, 12-month-old cant difference, there was also a trend for the clusterin/
mice (p 0.07) to have higher CSF A40. Taken together,PDAPP, apoE/ mice have almost exclusively thiofla-
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Figure 3. Hippocampal Levels of A40 and
A42 Are Elevated in 12-Month-Old PDAPP
Mice that Lack Both apoE and clusterin
As determined by ELISA, both A40 (A) and
A42 (B) is elevated in carbonate soluble hip-
pocampal lysates from PDAPP mice that are
apoE//clusterin/ (n  12) as compared to
PDAPP mice that are apoE//clusterin/
(n  10), apoE//clusterin/ (n  10), or
apoE//clusterin/ (n 12). (C) In carbonate
insoluble hippocampal lysates, A40 is in-
creased in PDAPP, apoE//clusterin/ and
apoE//clusterin/ mice as compared to
apoE and clusterin single knockouts. Also in
carbonate insoluble lysates, (D) A42 is in-
creased (though not significantly) in PDAPP,
apoE//clusterin/ and apoE//clusterin/
mice relative to the other genotypes.
these data suggest that apoE and clusterin both influ- clusterin/ mice suggests that apoE, and possibly clus-
ence CNS A40 levels but that apoE has a selective effect terin, are specifically influencing CNS A metabolism/
on A42. Unlike the CSF, there was no significant differ- clearance, we sought direct evidence for this possibility.
ence in plasma A40 or A42 levels between any of the We recently developed an in vivo microdialysis tech-
genotypes (Figure 5C and 5D). Further evidence that the nique to measure a specific pool of A in brain ISF in
effects that apoE and clusterin have on influencing A awake, freely moving mice (Cirrito et al., 2003). Utilizing
fate occur in the CNS is the finding that the CSF/plasma this technique, we first assessed baseline levels of A1-x
ratio of A40 and A42 was elevated in mice lacking apoE, that is exchangeable across a 38 kDa microdialysis
clusterin, or both molecules (Figure 5E and 5F). membrane (ISF eA) in 3-month-old PDAPP mice ex-
pressing apoE and clusterin, lacking each protein alone
or lacking both proteins. We found that, as in the CSF,apoE and clusterin Influence Interstitial Fluid A
ISF eA was significantly increased in apoE/ andLevels and Elimination Half-Life
apoE/, clusterin/ mice (Figure 6A). These elevatedAlthough the elevated levels of A40 and A42 in CSF
but not plasma of young PDAPP, apoE/ and apoE// levels were not due to differences between the groups in
Figure 4. Hippocampal Levels of A40 and
A42 Are Elevated in 3-Month-Old PDAPP
Mice that Lack Both apoE and clusterin
As determined by ELISA, both A40 (A) and
A42 (B) is elevated in carbonate soluble hip-
pocampal lysates from PDAPP mice that are
apoE//clusterin/ (n  10) as compared to
PDAPP mice that are apoE//clusterin/
(n  14), apoE//clusterin/ (n  12), or
apoE//clusterin/ (n 12). In carbonate in-
soluble hippocampal lysates, A40 (C) and
A42 (D) is also elevated in PDAPP, apoE//
clusterin/ mice relative to the other geno-
types.
apoE and clusterin Suppress A Deposition
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Figure 5. A40 and A42 Are Elevated in the
CSF but Not Plasma in PDAPP Mice that Are
Both apoE/ as well as in apoE/clusterin
Double Knockout Mice at 3 Months of Age
CSF levels of A40 and A42 are elevated in
PDAPP, apoE//clusterin/ (n  13), and
apoE//clusterin/ (n  11) as compared to
PDAPP, apoE//clusterin/ (n  14) and
apoE//clusterin/ (n  13). Plasma levels
of A40 (C) and A42 (D) were not significantly
different between the genotypes. The CSF/
plasma A40 ratio (E) was significantly ele-
vated in PDAPP, apoE//clusterin/ and
apoE//clusterin/ as compared to apoE//
clusterin/ mice while the CSF/plasma A42
ratio (F) was elevated in PDAPP, apoE//
clusterin/ mice relative to apoE//
clusterin/ animals. For (E) and (F), the CSF/
plasma ratio of A40 and A42 was determined
from the subset of PDAPP animals from each
group in which both CSF and plasma samples
were both obtained: apoE//clusterin/
(n 11), apoE//clusterin/ (n 9), apoE//
clusterin/ (n  13), and apoE//clusterin/
(n  8).
the percent ISF eA1-x recovered within the microdialysis quantitative Western blotting, we found that the levels
of apoE were not significantly different in 3-month-oldprobe as assessed by the interpolated zero flow method
(Figure 6B) (Menacherry et al., 1992). To determine if PDAPP versus PDAPP, clusterin/ mice (Figure 7A). In
contrast, PDAPP, apoE/ mice had significantly lowerapoE or clusterin influence extracellular A metabolism
via a mechanism independent of an effect on A synthe- levels of clusterin than PDAPP mice (Figure 7B). Interest-
ingly, this suggests that part of the A-related pheno-sis, we determined the net elimination rate of ISF eA1-x
following inhibition of A production by a potent type in apoE/ mice may be due to decreased levels
of clusterin.-secretase inhibitor, LY411575, as described (Cirrito et
al., 2003). As we showed previously, the net elimination While it seemed likely that the effects of apoE and
clusterin that we observed were due to the ability ofhalf-life of ISF eA1-x in young PDAPP mice expressing
apoE and clusterin was 2 hr (Figures 6C–6E). Interest- both molecules to bind A and influence its metabolism,
it remained possible that apoE and clusterin were di-ingly, the net elimination half-life of ISF eA1-x was signifi-
cantly decreased and was only 1 hr in both apoE/ rectly or indirectly influencing APP levels or cleavage to
affect A steady-state levels. Since cholesterol levelsand apoE//clusterin/ mice (Figures 6C–6E). Taken
together, these results demonstrate that one role for could influence A synthesis, we measured the level of
brain cholesterol in PDAPP mice in the presence of apoEendogenously produced apoE is to regulate extracellu-
lar metabolism of soluble A prior to the onset of AD- and clusterin, in the absence of each molecule alone,
or in the absence of both molecules. There was no differ-like pathology by a process that is independent of A
synthesis. ence in brain cholesterol levels between any of the geno-
types (data not shown). To test the possibility of altered
A generation, we measured levels of full-length humanapoE Influences clusterin Levels but Neither
Molecule Influences APP Processing APP as well as APP C-terminal fragments (CTFs) in
PDAPP mice in the presence and absence of apoE andAlthough the greatest effects on A metabolism, and
ultimately deposition, appeared to be from a cumulative clusterin. Levels of both full-length APP as well as both
	 and  CTFs were not influenced by the expression ofeffect of lacking apoE and clusterin, the single knock-
outs each demonstrated alterations in deposited and apoE or clusterin (Figures 7C and 7D). Similar results
were obtained when analyzing APP mRNA and proteinsoluble A (Figures 2, 3, and 5). Therefore, we asked
whether any effects on A metabolism in single knock- in apoE/ mice in a previous study (Bales et al., 1999).
Thus, we found no evidence that apoE or clusterin influ-out mice were influenced by altered levels of one mole-
cule in the absence of the other. As assessed by semi- ence A synthesis.
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Figure 6. Baseline ISF A and Half-Life of ISF A Elimination Is Altered in PDAPP Mice that Are apoE/ and apoE/clusterin Double Knockout
(A) The baseline concentration of ISF eA1-x, as assessed by in vivo microdialysis, is significantly elevated in PDAPP mice that lack apoE or
apoE/clusterin. Values of ISF eA1-x (pg/ml) in apoE//clusterin/ are 973.5 
 274.2 (n  8) as compared to 2261.0 
 500.6 (n  8, p 
0.0407) in apoE//clusterin/ and 2313.0 
 274.2 (n  9, p  0.0108) in apoE//clusterin/.
(B) In vivo percent recovery determined with the interpolated zero flow method. There was no significant difference in A recovery within the
microdialysis probe in any of the groups analyzed (repeated measures ANOVA with Huynh and Feldt adjustment).
(C) In all groups studied, the baseline concentration of ISF eA1-x declined within several hours of a 3 mg/kg s.c injection of a -secretase
inhibitor (LY411575) and reached a new, lower baseline after 4–6 hr after treatment.
(D) The log of the percent baseline concentration of ISF eA1-x versus time was linear in all four groups studied, suggesting net first order
kinetics of A elimination from ISF.
(E) In apoE//clusterin/ and apoE//clusterin/ mice, the half-life of A elimination was 2.38 
 0.445 (n  5) and 2.17 
 0.261 (n  6)
hours, respectively. In apoE//clusterin/ and apoE//clusterin/ mice the half-time of ISF eA1-x was 1.16 
 0.058 (n  5) and 1.07 
 0.432
(n  6) hr, respectively. In the latter groups, the eA elimination half-life was significantly shorter compared to mice that expressed both apoE
and clusterin (p  0.0478 and p  0.0143, respectively).
Discussion in soluble A clearance, in vivo evidence for such a role
has been lacking. Herein, we demonstrate that, in the
absence of both apoE and clusterin, there was an unex-APOE genotype is the only proven genetic risk factor
for AD and cerebral amyloid angiopathy (CAA) (Sch- pected and striking phenotype, with both early onset
and greater levels of A deposition in PDAPP mice. Themechel et al., 1993; Greenberg et al., 1995; Strittmatter
and Roses, 1996; Nicoll et al., 1997; Wisniewski et al., magnitude of the effect of removing both molecules on
A levels and onset of deposition was similar in extent1997). While there are several possible mechanisms as
to how apoE may be involved in AD and CAA pathogene- to that described for overexpressing presenilin muta-
tions in APP transgenic mice (Duff et al., 1996; Borcheltsis, there is strong in vitro (Strittmatter et al., 1993b;
LaDu et al., 1994; Ma et al., 1994; Tokuda et al., 2000) et al., 1997). In contrast to the presenilin mutations that
affect A generation, our data utilizing in vivo microdi-and in vivo (Bales et al., 1997; Holtzman et al., 2000a)
evidence that apoE/A interactions in some way play a alysis shows that an important effect of apoE is to influ-
ence extracellular A metabolism by a process that ismajor role. In addition to apoE, clusterin is the other
abundantly expressed apolipoprotein in the brain. Simi- independent of A synthesis. A further understanding
of the specific pathways by which apoE regulates CNSlarly, in vitro (May and Finch, 1992; Oda et al., 1995;
Boggs et al., 1996; Matsubara et al., 1996; Lambert et A metabolism is likely to provide an important insight
into AD and CAA pathogenesis and treatment.al., 1998) and in vivo (DeMattos et al., 2002c) studies
have shown that clusterin/A interactions play an impor- The discovery of apoE and clusterin colocalized to
A deposits in both AD and CAA prompted researcherstant role in amyloid formation and toxicity. Previous
studies in which APP transgenic mice were bred to either to speculate that both molecules might function as
“pathological chaperones” (Wisniewski and Frangione,apoE/ or clusterin/ mice revealed a clear role for each
molecule in facilitating the conversion of soluble A into 1992; Calero et al., 2000). In addition to their association
with fibrillar forms of A, apoE and clusterin were foundforms with a high  sheet content (e.g., amyloid fibrils)
(Bales et al., 1997, 1999; DeMattos et al., 2002c). While to associate with soluble A in body fluids, including
CSF and plasma (Ghiso et al., 1993; Matsubara et al.,a role for apoE and clusterin has also been suggested
apoE and clusterin Suppress A Deposition
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Figure 7. Lack of apoE Expression Influ-
ences clusterin Levels While apoE and clus-
terin Do Not Influence APP Processing
(A) The hippocampus of 3-month-old PDAPP,
apoE//clusterin/ mice (n  8) has similar
levels of apoE as in apoE//clusterin/ (n 
8) mice. Inset shows representative Western
blot for apoE.
(B) The hippocampus of 3-month-old PDAPP,
apoE//clusterin/ mice (n  8) has signifi-
cantly increased levels of clusterin as com-
pared to apoE//clusterin/ mice (n  8).
Inset shows representative Western blot for
clusterin.
(C) Representative Western blot for full-
length APP and APP C-terminal fragments
reveals no apparent difference between the
levels of APP, 	-CTF, or -CTF levels be-
tween PDAPP mice of different genotypes.
(D) Quantification of -CTF levels from West-
ern blots revealed no significant difference
between PDAPP mice of different genotypes
(n  8 per group). There was also no signifi-
cant difference between 	-CTF or full-length
APP levels between the groups.
1999; Fagan et al., 2000). Several biochemical studies stitial fluid of the brain, an extracellular compartment
that is continuous with CSF. If these interactions influ-have shown that different forms of apoE and clusterin
can bind and form complexes with purified A (Strittmat- ence A metabolism independent of an effect on A
synthesis or aggregation, one would predict that levelster et al., 1993b; LaDu et al., 1994; 1995). There is also
evidence from cell culture studies that apoE/A and of soluble A would be altered in the absence of these
molecules when assessed prior to A deposition. In-clusterin/A complexes can be internalized by some
cells via specific cell surface receptors (Hammad et al., deed, there was a highly significant increase in both
A40 and A42 in the CSF of young apoE/clusterin double1997; Urmoneit et al., 1997; Beffert et al., 1999; Yang et
al., 1999). Blood-brain barrier transport studies have knockout mice. A smaller but still significant increase
was also found in apoE/ mice. The fact that theseshown that clusterin can facilitate transport of 125I-A
from blood into brain (Zlokovic et al., 1996) and that, changes were found in CSF but not plasma suggests
that an effect of apoE and/or clusterin may be via localfollowing CNS injections of 125I-A into brain, there was
significant transport from brain to blood that was lower effects on A metabolism in the CNS.
Our studies utilizing in vivo microdialysis to assessin young apoE/ mice (Shibata et al., 2000). While these
studies suggest a possible role of apoE and clusterin in ISF A and its net elimination rate demonstrate that
apoE regulates extracellular clearance pathways of sol-A transport and clearance, there has been no direct
evidence that endogenously produced apoE or clusterin uble A. On the surface, it may seem contradictory that
the concentration of A in the ISF is higher in apoE/regulates metabolism/elimination of endogenously pro-
duced A. Utilizing APP transgenic mice, we have shown and apoE//clusterin/ mice while the half-life of ISF
eA elimination is shorter. The finding, however, is notthat CNS expression of apoE2, apoE3, and apoE4 (in
the absence of murine apoE) resulted in a marked delay unexpected if apoE is affecting the fate of extracellular
A in the brain. The results are consistent with apoE(6–15 months) in A deposition relative to mice that
express normal levels of murine apoE or no apoE (Holtz- binding to a pool of extracellular A, resulting in its
retention in the brain parenchyma. Immunoprecipitationman et al., 1999, 2000a; Fagan et al., 2002). The delay
in A deposition induced by the expression of human studies have shown that apoE forms complexes with
soluble A in brain (Russo et al., 1998). apoE could thusapoE in the CNS suggested a possible role for apoE in
A metabolism, perhaps via effects on clearance. facilitate local clearance of apoE/A complexes. For
example, in vitro studies have shown that apoE/A com-The current study strongly demonstrates that apoE
and clusterin cooperatively suppress A deposition and plexes can be taken up by cells via LDL receptor family
members (Hammad et al., 1997; Urmoneit et al., 1997;that apoE is contributing to this effect via directly influ-
encing the metabolic fate of soluble, extracellular A. Beffert et al., 1999; Yang et al., 1999). At the same time
as affecting clearance, apoE is also likely to be increas-In PDAPP mice, human A is produced and secreted
almost exclusively in the CNS by neurons (DeMattos et ing A residence time in the extracellular space by alter-
ing its diffusion in the parenchyma. Data directly sup-al., 2001). Thus, human A present in the brain extracel-
lular space (interstitial fluid and CSF) as well as in the porting this possibility is that the location within the
hippocampus that A deposits differs in the presenceplasma is derived from CNS neurons. apoE and clusterin
are produced and secreted predominantly by astrocytes versus the absence of apoE (Bales et al., 1997; Holtzman
et al., 1999, 2000a). In the presence of apoE, a largein the CNS (Boyles et al., 1985; May and Finch, 1992).
The first interaction between the apolipoproteins (apoE amount of A deposition occurs in the molecular layer
of the dentate gyrus. In its absence, there is depositionand clusterin) and the A peptide will occur in the inter-
Neuron
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in the hilus but no deposition in the molecular layer. deposition (R.B.D. and D.M.H., unpublished data).
How apoE alters A diffusion is not known; however, Whether increased expression of apoE2, apoE4, or hu-
apoE is known to bind strongly to heparan-sulfate pro- man clusterin will result in positive or negative effects
teoglycans (Strittmatter and Bova Hill, 2002) and to the has not been determined. Understanding the details of
extracellular matrix in vivo (Williams et al., 1995). We how human apoE influences A metabolism is likely to
found that A levels were increased in both ISF and CSF provide useful information in both understanding patho-
in apoE/ mice. In the absence of apoE, a pool of A genesis as well as developing new treatment ap-
would not be retained in brain parenchyma, and it could proaches.
more easily diffuse in the ISF, resulting in higher CSF
levels and a faster elimination rate from the ISF pool.
Experimental ProceduresEvaluation of the role of specific LDL receptor family
members and of components of the extracellular matrix Animals and Tissue Preparation
that influence apoE-regulated A clearance and diffu- PDAPP mice homozygous for the APPV717F transgene that (1) ex-
sion will likely lead to further insights into this process. pressed clusterin and apoE (apoE/, clusterin/) (Games et al.,
1995; Bales et al., 1997), (2) were apoE/ (Bales et al., 1997), or (3)Prior studies with APP transgenic mice showed that,
were clusterin/ (DeMattos et al., 2002c) were utilized in this study.in the absence of either apoE or clusterin alone, there
PDAPP, apoE/, clusterin/ mice were produced by breedingwas a similar onset to A deposition (8–9 months of
PDAPP, apoE/ and PDAPP, clusterin/ mice together for two gen-
age) but that most A deposits in the absence of either erations. All mice analyzed were on the same genetic background.
molecule were thioflavine-S negative (non- sheet, dif- Animal genotype was identified by PCR as described (Bales et al.,
fuse plaques). If apoE and clusterin’s only role in influ- 1997; Sun et al., 1998; McLaughlin et al., 2000). Tissue analysis was
performed as described at 3, 6, and 12 months of age (Holtzman etencing the fate of A was to increase the probability of
al., 2000b; DeMattos et al., 2002c). CSF was collected as describedfibril formation, one would have expected that PDAPP,
(DeMattos et al., 2002b).apoE/clusterin double knockout mice to never develop
fibrillar Adeposits (i.e., amyloid) as each molecule inde-
pendently contributes to fibril formation. This was not Histological Analysis
the case. apoE was shown to directly influence the extra- Tissue sections were cut in the coronal plane at 50 m on a freezing
sliding microtome from the genu of the corpus callosum throughcellular fate of soluble A in the CNS. Since both apoE/
the caudal extent of the hippocampus. The percent surface areaand apoE//clusterin/ mice had a similar net half-life
covered by A IR deposits (percent A load) as identified with aof ISF Aelimination, there must be a factor in addition to
rabbit pan-A antibody (Biosource International, Camarillo, CA) was
apoE’s effect on A clearance that leads to the additive quantified following stereological principles as described (Holtzman
phenotype of A deposition beginning earlier and accu- et al., 2000a). Thioflavine-S staining was performed as described
mulating to a greater extent in apoE//clusterin/ mice. (Bales et al., 1997). A and thioflavine-S load were determined in
the cingulate cortex and hippocampus in three sections, each sepa-A likely explanation for this phenotype relates to the
rated by 300 m.elevated levels of CSF A40. While A40 and A42 are
increased in the CSF of both apoE/ and apoE//
clusterin/ mice, A40 is significantly higher in apoE// A Quantification
clusterin/ as compared to apoE/ mice. While high Measurement of A40 and A42 levels in plasma, CSF, or brain tissue
levels of A42 drive A deposition (especially diffuse was performed as described (Johnson-Wood et al., 1997; DeMattos
et al., 2002a, 2002b). In order to evaluate the carbonate soluble andplaques), if A42 levels are similar in two groups of ani-
insoluble pools of A from brain tissue, we performed a carbonatemals, there is evidence that a higher A40 and A 40/42
extraction (100 mM carbonate, 50 mM NaCl, protease inhibitors, pHratio can drive earlier deposition of fibrillar A or true
11.5) of hippocampal and cortical tissue (1:20, wt:vol) on ice. Tissue
amyloid (Fryer et al., 2003). In fact, apoE/clusterin double samples were dounce homogenized and spun in a microcentrifuge
knockout mice had greater thioflavine-S load even when at 14,000 RPM for 15 min at 4C. The supernatant was placed in a
adjusted for total A IR deposits than did apoE or clus- fresh tube on ice, and the pH of the lysate was neutralized to 7.4
terin single knockout mice. In addition, neuritic dystro- with 1 M Tris (pH 6.8). A40 and A42 levels were then determined
on the carbonate soluble supernatant and pellet as noted above.phy was just as severe in apoE//clusterin/ mice as
A1-x levels in ISF were analyzed as described (Cirrito et al., 2003).in mice expressing these molecules. Thus, while apoE
and clusterin can facilitate A fibril formation, they are
not required for A-induced structural change that re- In Vivo Microdialysis
sults in neuritic dystrophy. Perhaps the rate of aggrega- In vivo microdialysis to assess brain ISF A1-x in the hippocampus
tion and resulting A conformation, both of which may of awake, freely moving PDAPP mice was performed exactly as
described (Cirrito et al., 2003). For treatment with the -secretasebe controlled by A chaperones, are important factors
inhibitor LY411575, mice were injected subcutaneously with 3 mg/in this process.
kg LY411575 in corn oil.These findings have important mechanistic implica-
tions for potential treatment strategies. For A binding
molecules such as apoE and clusterin that can bind to Western Blotting
both soluble and other forms of A, the absolute level Western blotting for apoE, clusterin, and APP were performed as
described (Sun et al., 1998; Han et al., 2001). Forty micrograms ofof expression and the particular species and isoform
protein was loaded per lane. To detect full-length APP and APPof the molecule has the potential to influence both A
C-terminal fragments, the blot was probed with CT15 (a kind gift fromfibrillogenesis and metabolism to differing extents.
Dr. Ed Koo, University of California, San Diego), a rabbit polyclonal
While increased expression of murine apoE alone ap- antibody against the terminal 15 amino acids of APP (Sisodia et al.,
pears to favor A deposition and fibrillogenesis (Bales 1993). Image was captured using the Kodak ImageStation 440CF.
et al., 1999), increased expression of apoE3 in the brain Densitometry and standard curves were generated using the Kodak
1D Image Analysis software.results in a dose-dependent decrease in A levels and
apoE and clusterin Suppress A Deposition
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Statistical Analysis D.M. (2002a). Brain to plasma amyloid- efflux: A measure of brain
amyloid burden in a mouse model of Alzheimer’s disease. ScienceData in figures represent mean 
 SEM. All statistical analysis was
performed using PRISM V.3.00 (GraphPad, San Diego) for WIN- 295, 2264–2267.
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